QURE has been in the news 563% more than usual
Feb 20, 2026, 11:36 AM
-37.43%
What does QURE do
uniQure NV, headquartered in Amsterdam, specializes in gene therapies and employs 480 staff, focusing on one-time treatments for genetic diseases. Their lead candidates include AMT-061 for hemophilia B and AMT-130 for Huntington's disease.
QURE has been in the news recently: uniQure N.V. is facing securities class action lawsuits alleging misleading statements for investors who bought shares between September 24 and October 31, 2025. The Schall Law Firm and DJS Law Group have notified eligible uniQure investors and shareholders to contact them by the April 13, 2026 lead-plaintiff deadline.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.